Atossa Therapeutics, Inc. ATOS NASDAQ

Atossa Therapeutics, Inc. (ATOS) reported total assets of $47.61M and total liabilities of $8.26M for fiscal year 2025, resulting in total equity of $39.35M.

The company held $41.3M in cash and short-term investments. Total debt stood at $0.00, with net debt of $-41.3M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 5.53, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 5.53 — balance sheet is strong
• MOAT (28/100) — Total assets $47.61M and equity $39.35M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 55/100 with 3/7 criteria passed.

NVAX

Novavax, Inc.

$8.69

+3.58%

OCGN

Ocugen, Inc.

$1.95

+8.33%

PALI

Palisade Bio, Inc.

$2.34

+13.59%

TNXP

Tonix Pharmaceuticals Holding Corp.

$14.34

+7.42%

VXRT

Vaxart, Inc.

$0.71

+4.41%

INO

Inovio Pharmaceuticals, Inc.

$1.19

+7.21%

IBIO

iBio, Inc.

$2.10

-4.11%

ELEV

Elevation Oncology, Inc.

$0.37

-2.12%